Welcome!

Virtualization Authors: Roger Strukhoff, Pat Romanski, Elizabeth White, Don MacVittie, Jason Bloomberg

News Feed Item

Mobile MIM for Diagnostic Imaging Surpasses 250,000 Downloads

CLEVELAND, Nov. 19, 2012 /PRNewswire/ -- MIM Software Inc., a leading global provider of medical imaging software, announced today that Mobile MIM™ has exceeded 250,000 downloads on the Apple® App Store.

(Photo: http://photos.prnewswire.com/prnh/20121119/CL16035)

Through the development of Mobile MIM and other new technologies, MIM Software™ has achieved distinction in the medical imaging field and is influential in initiating and driving market standards.  Mobile MIM was the first FDA-cleared medical imaging app for the iPad® and iPhone® and provides remote diagnostic viewing of CT, PET, MRI, SPECT, ultrasound, and X-ray, as well as radiation therapy treatment plan review and approval.

Mobile MIM was designed to equip physicians with diagnostic tools for remote consultation with peers, specialists, and referring physicians.  The accessibility provided by Mobile MIM can limit redundant and unnecessary imaging procedures across facilities and simplify communication between caregivers to provide the best possible patient care.  The app was included in the Apple App Store Rewind for best Medical Software in 2011, and was named Best New Radiology Software by AuntMinnie.com the same year.  

To learn more, visit www.mimsoftware.com or call 866-421-2536.

MIM Software Inc. provides practical imaging solutions in the fields of radiation oncology, radiology, nuclear medicine, neuroimaging, and cardiac imaging.  MIM® offers solutions for PC and Mac® workstations, as well as mobile iOS and cloud-based platforms.  MIM is a privately held company that sells its products globally to imaging centers, hospitals, specialty clinics, research organizations, and pharmaceutical companies.

SOURCE MIM Software Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.